September 21, 2018

A leader in the biotech industry, REGENXBIO is developing technologies critical to the success of innovative gene therapy products with the potential to cure a range of devastating diseases. Find out how Chardan enabled the growth of this groundbreaking platform.

A Fruitful Start

First, we helped REGENXBIO management define objectives. Together, we crafted a compelling story to share with institutional investors and venture capital funds during a two-week, Chardan-hosted roadshow. The result: a meaningfully upsized Series D financing of $70.5 million.

$70.5 million

Series D

Sole Placement Agent

May 2015

Going Public

Following the Crossover round financing, Chardan facilitated the formation of the IPO syndicate and through the assisted the book runners in the successful $159.4 million IPO.

$159.4 million



September 2015

Post-IPO Follow-Through

Chardan continued to support the company through marketing activities—including European and US roadshows, leadership calls, and KOL events—and acted as a co-manager on their first follow-on.

$87.2 million



March 2017

Thank You!

We've received your information, and we're processing your request.

Get In Touch

17 State Street
Suite 2130
New York, NY 10004

One East Putnam Ave, 4th Fl. Greenwich, CT 0680

+1 646-465-9000

All fields required